• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Innoblative taps ex-Lumicell chief Londy for CEO | Personnel Moves, Sept. 13, 2019

Innoblative taps ex-Lumicell chief Londy for CEO | Personnel Moves, Sept. 13, 2019

September 13, 2019 By Brad Perriello

Innoblative Designs CEO Kelly Londy

Innoblative Designs last week named former Lumicell chief executive Kelly Londy as its new CEO.

Apart from her two-year stint at the Lumicell helm, Londy was COO at Accuray (NSDQ:ARAY) and worked at GE Healthcare and Philips Healthcare.

“Innoblative’s Sira RF ablation device offers unique capabilities that address shortcomings in the current advanced energy surgical market,” Londy said in prepared remarks. “I am thrilled to join this dynamic team and look forward to commercializing this next-generation RFA technology to improve the surgical experience for both physicians and patients.”

“We are delighted to welcome Kelly and her passion for innovation and patient-focused medical device solutions,” added co-founder & director Tyler Wanke. “Kelly brings a wealth of knowledge and experience in the MedTech market, specifically in diagnostic and therapeutic devices for cancer, making her an ideal fit to lead the company as we launch our commercial activities and additional clinical studies.”

 Cala Health J&J venture exec Ryan for CEO
Medical wearables maker Cala Health last week said it named Renee Ryan as CEO, replacing founder Kate Rosenbluth, who’s slated to assume the chief scientific officer role.

As VP of venture investments at Johnson & Johnson Innovation, Ryan led that firm’s investment in Cala’s Series A round and 15 other investments.

“I have long admired Kate’s scientific prowess and am excited by the near-term potential of Cala Trio for essential tremor, as well as our bioelectronic non-invasive neuromodulation platform for multiple chronic diseases,” Ryan said in prepared remarks. “I’m thrilled and proud to see the swift trajectory of the company, including the recent $50 million Series C funding, and the phased launch of Cala Trio in the United States. I look forward to working with Kate and the talented team at Cala Health to maintain this momentum as we transition to a commercial organization.”

“I’m very pleased to partner with Renee to fuel the healthy growth and expansion of Cala Health,” Rosenbluth added. “Moreover, I’m excited to continue advancing our new products and realizing our vision to transform the standard of care for chronic disease with neuromodulation therapies.”
Read More

 Alpha Tau Medical names Den as CMO
Alpha Tau Medical last week named Dr. Robert Den as its chief medical officer.

Den was an associate professor of radiation oncology at Thomas Jefferson University in Philadelphia.

“I envision alpha emitting radiation-based therapy being employed across multiple malignancies, either as primary therapy or in conjunction with immuno-oncology treatments. We have only scratched the surface of the potential indications for this technology. I am privileged to join the Alpha Tau team and take part in this exciting revolution in radiation oncology,” Den said in prepared remarks. “The prospects for Alpha DaRT are tremendous, and I look forward to helping clinicians around the world unleash its full potential.”

“I am glad to see leaders in their fields continuing to join Alpha Tau,” added CEO Uzi Sofer. “Having Dr. Den leading our medical team will be essential for our clinical efforts, especially as we approach the upcoming initiation of our clinical trials in the U.S. and Canada, and discussions with regulators on a potential marketing approval. Bobby brings a unique mix of medical and clinical expertise that will serve us well as we rapidly expand the base of practitioners providing this potentially life-saving treatment to patients in need.”
Read More

 Orchestra BioMed promotes Cordis vet Donohoe to CMO
Orchestra BioMed last month appointed Dr. Dennis Donohoe, a longtime veteran of former Johnson & Johnson (NYSE:JNJ) subsidiary Cordis, as its full-time chief medical officer.

Donohoe was part-time CMO at Orchestra BioMed’s Focal Therapies group and its predecessor, Caliber Therapeutics, under a consulting agreement.

“I am excited to assume a full-time role as part of Orchestra BioMed’s leadership team during this critical growth period when I can help advance the development of Virtue SEB for coronary and peripheral artery disease as well as BackBeat CNT for targeted high blood pressure patient populations,” Donohoe said in prepared remarks. “As a physician, I was impressed by how these therapies have the potential to improve outcomes in areas of high unmet medical need while seamlessly integrating into existing clinical workflows within interventional cardiology and cardiac rhythm management. I truly believe that eventual regulatory approval and adoption of these technologies could have a lasting impact for patients, physicians and hospital systems worldwide.”

“Dennis Donohoe is a proven leader with extensive clinical and regulatory experience directly relevant to our therapeutic device product pipeline. We are thrilled that Dennis has agreed to join our management team on a full-time basis,” added chairman & CEO David Hochman. “We could not ask for a more qualified leader as we prepare to initiate a global clinical and regulatory development program focused on multiple coronary and peripheral indications for Virtue® SEB in collaboration with Terumo, our strategic partner. His extensive knowledge and expertise will also be vital to further our clinical and regulatory plans for BackBeat CNT for hypertension, our other flagship product, as well as additional pipeline development initiatives we expect to embark on in the future.”
Read More

 MiMedx GC Haden scales back
MiMedx (NSDQ:MDXG) last month inked a consulting agreement with former general counsel & secretary Alexandra Haden for up to 40 hours a month through February 2020, at $8,000 per month plus nine months’ severance ($476,250).
Read More

  • Obalon Therapeutics hires first medical director for retail clinic
  • Ozop Surgical names ortho vet Ansari as sales & marketing EVP
  • Shine Medical Technologies names Buurlage as European ops VP
  • Podichetty out as Irras clinical affairs VP, Insanally in as regulatory affairs head, Asbury named project engineering head
  • Donato tapped for chief business officer at Genetesis

Filed Under: Business/Financial News, Featured Tagged With: Alpha Tau Medical, Cala Health, Genetesis, Innoblative Designs, IRRAS, MiMedx Group Inc., Obalon Therapeutics, Orchestra BioMed, Ozop Surgical, Personnel Moves, Shine Medical Technologies

In case you missed it

  • DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently
  • ReWalk Robotics closes $40M private placement
  • Fusion Robotics wins FDA clearance for 3D imaging robotic targeting system
  • FDA authorizes Q-Collar to help protect athletes’ brains
  • The top 7 medtech CEO quotes on COVID-19, one year later
  • Forest Devices touts study of stroke detection tech
  • iRhythm’s revenue jumps 33% in Q4
  • Thermo Fisher completes Mesa Biotech acquisition
  • ICU Medical dips despite Street-beating Q4
  • Silk Road Medical touts results of large TCAR study
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
  • 8 drug delivery innovations you need to know
  • Terumo to acquire Health Outcomes Sciences
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • NuVasive reports mixed Q4 results
  • Is J&J’s COVID-19 vaccine linked to tinnitus?
  • UK passes post-Brexit medical device regulation

RSS From Medical Design & Outsourcing

  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]
  • Interpower debuts plugs in new colors
    Interpower announced that its NEMA 5-20 hospital-grade plugs for use in North America now come in molded colors of clear, black or gray on 10-foot lengths of flexible cord. These molded plugs complement the company’s NEMA 5-20 hand-wired hospital-grade plugs. The North American 18A hospital-grade power cord on 14 AWG SJT cable and North American… […]
  • Portescap motors gain certification
    Portescap announced that its slotless brushless DC motors for respirators have received ISO 13485:2016 certification. Expanding on ISO 9001, this standard contains specific requirements for parts traceability and risk management activities throughout the design and development stages. It also requires process and software validations at defined intervals. Independent risk management and quality compliance firm DNV… […]
  • Instron launches update to product testing system
    Materials testing equipment and software developer Instron announced the launch of the Torsion Add-On 3.0 for universal testing systems. Recently redesigned to take advantage of the latest functionality offered by the new Instron 6800 series, this system offers a simpler, safer, and more intuitive user experience, according to Norwood, Mass.-based Instron. Instron introduced the Torsion… […]
  • Abiomed CEO Michael Minogue appointed as AdvaMed chairperson
    Medtech trade group AdvaMed today said it has appointed Abiomed (NSDQ:ABMD) president and CEO Michael Minogue as chairperson of the AdvaMed board of directors, effective immediately. Minogue will serve as chairperson of the trade association’s board of directors for two years. He has been a member of the board since 2007 and a member of the board… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS